September 1, 2023 We are excited to announce that Dr. Yosef Landesman has joined Akttyva's team as a Drug Discovery and Translational Research Advisor. Dr. Landesman brings over 20 years of translational drug-discovery experience with taking drugs from discovery through all stages of development and to the market at Karyopharm and making crucial contributions as a Chef Scientific Officer at HC Biosciences and Alnylam.
December 14, 2021 Honored to announce a National Science Foundation (NSF) award to further develop and commercialize our AIDE-360 platform that aims at facilitating the rational design of therapeutics addressing vascular leak disorders. This highly competitive award is a demonstration of innovative nature and commercial potential, the two main criteria for NSF grant review. This grant will allow us to accelerate the 2nd generation AIDE-360 and develop the commercialization plan. More about the program: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2136307&HistoricalAwards=false
November 17, 2021. Akttyva Therapeutics won an IBM prize for its AI drug-discovery program AIDE-360, which was used to discover the hits for the vascular leak program
October 1, 2021. Akttyva Therapeutics is a finalist of the highly selective 2021 MassChallenge competition! We are honored to be one of only 45 companies out of 229 selected for the final round (out of over 3,000 original applications). The winners of the final round will compete for $1M non-dilutive cash prizes competition
April 1, 2021 Akttyva has established laboratories in Mansfield Bioincubator
January 10, 2021 Dr. Mario DiPaola, an experienced scientist and successful entrepreneur, joins Akttyva as Head of Research.